This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PRX-8066

Allergan plc

Drug Names(s): PRX-08066

Description: PRX-08066 is a highly selective, small-molecule 5-HT2B antagonist. Studies have shown that antagonists, or inhibitors, of a specific GPCR known as 5-HT2B can selectively dilate diseased pulmonary blood vessels without affecting normal pulmonary or systemic vessels. 5-HT2B antagonists may also potentially slow the progression of the disease by blocking the smooth muscle cell proliferation that leads to progressive thickening of pulmonary vessels.

Deal Structure: PRX-08066 was originally developed by Epix.

Clinical Data and Epix
In September 2009, Clinical Data purchased at auction all the assets related to the PRX-08066 drug program from Epix.

Forest and Clinical Data
In February 2011, Forest Laboratories and Clinical Data entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data. In April 2011, Forest Laboratories announced that it has successfully completed its acquisition of Clinical Data.

Forest and Actavis
In February 2014, Actavis and Forest announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares for each share of Forest common stock).

In July 2014, Actavis announced that it has completed the acquisition of Forest in a cash and equity transaction currently...See full deal structure in Biomedtracker


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug